You are here: Industry Insights > Romosozumab

News List

Romosozumab Increases Bone Formation, Cuts Bone Resorption drugs
July 02, 2019
Romosozumab Increases Bone Formation, Cuts Bone Resorption.
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture drugs
April 11, 2019
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture.
Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab) worldpharmanews
January 21, 2019
Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab)
EVENITY (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture firstwordpharma
January 09, 2019
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fr
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture firstwordpharma
December 02, 2018
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVE
EMA accepts Marketing Authorization Application for romosozumab in the treatment of osteoporosis europeanpharmaceuticalreview
January 09, 2018
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture…
Romosozumab provides protection against fractures in osteoporosis europeanpharmaceuticalreview
September 22, 2017
A new treatment for osteoporosis provides major improvements in bone density and fractures than the current standard treatment…